Pharmaceutical

Actavis Receives FDA Approval of Atomoxetine HCl Capsules

September 01, 2010

No release date set for Atomoxetine
 

Pfizer to Acquire FoldRx Pharmaceuticals

September 01, 2010

Lead product candidate tafamidis meglumine in EU Registration
 

MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence

August 31, 2010

Second FDA-Approved Drug Based on MonoSol Rx's PharmFilm® Technology
 

pSivida Announces Iluvien® Receives FDA Priority Review for Treatment of Diabetic Macular Edema

August 31, 2010

Reduces the review time goal from 10 months to six months
 

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

August 30, 2010

Original PDUFA goal date was August 30, 2010
 

Meda acquires Alaven, a US specialty pharma company

August 30, 2010

Strengthens position in the strategic US market
 

Medicis Announces Approval of Additional Strengths of Solodyn(R)

August 30, 2010

Three New Strengths Provide Greater Solodyn Dosing Precision
 

Novartis receives FDA approval of Tekamlo

August 27, 2010

A single-pill combination of aliskiren and amlodipine to treat high blood pressure
 

Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism

August 26, 2010

Therapy May Represent Novel Approach to Treating the Repetitive Behaviors and Social Deficits of Autism
 

Novartis Completes Purchase from Nestlé of Majority Interest in Alcon

August 26, 2010

Novartis now controls approximately 77 percent of Alcon's outstanding shares
 

Eisai Announces Positive Phase III Trial Results for Perampanel in Epilepsy

August 24, 2010

First in a series of Phase III clinical trials
 

Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey

August 23, 2010

Actively recruiting top talent to support US market penetration
 

FDA panel recommends broader use of Eli Lilly's Cymbalta

August 20, 2010

Committee votes positively regarding the overall safety profile of Cymbalta
 

Perrigo Confirms Filing for Clobetasol Shampoo

August 19, 2010

Announcement of Patent Infringement Lawsuit by Galderma
 

Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate

August 18, 2010

Biogen Idec expects to initiate Phase 3 program in the first half of 2011
 

Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials

August 17, 2010

Decision does not affect other Lilly Alzheimer's compounds in development
 

DUSA Pharmaceuticals Receives Response From FDA on Orphan Drug Designation Status

August 06, 2010

Orphan Drug Designation must target a disease that affects fewer than 200,000 patients in the U.S.
 

Cypress Bioscience Responds to Unsolicited, Non-Binding Proposal and Recent Letter From Ramius LLC

August 06, 2010

Proposal thoroughly review by Board of Directors and financial and legal advisors
 

Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology

August 05, 2010

Depomed will receive a $5 million upfront license fee
 

FDA Approves New Taxotere® (docetaxel) Injection Concentrate Formulation

August 05, 2010

1-vial Taxotere offers simplified preparation
 

Cypress Bioscience Announces Agreement to Discontinue Co-Promotion of Savella(R) With Forest Laboratories

August 04, 2010

Withdrawal From Commercial Market Will Result in Annual Savings of $10 Million
 

Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals

August 03, 2010

Company Expands Product Portfolio, Adds Drug Delivery Technology
 

Aragon Pharmaceuticals Appoints Richard A. Heyman CEO

August 02, 2010

Company Adds Ronald M. Evans and David J. Mangelsdorf to Scientific Advisory Board